TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8416053
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg of Protirelin (synthetic TRH) intravenously
Study: 2939126
Drug: Increased plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased plasma folate to 13 ng/ml or above
Study: 30561229
Drug: SB5 administered
Normalized name: SB5+
DrugBank: Pentavalent Antimony (DB13047)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB5 administered via autoinjector (AI)
Study: 30561229
Drug: SB5 administered
Normalized name: SB5+
DrugBank: Pentavalent Antimony (DB13047)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB5 administered via prefilled syringe (PFS)
Study: 25436296
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg ramosetron 1 hour before ingestion of a test meal (200 kcal per 200 mL, containing 100 mg 13C acetate)
Study: 21953277
Drug: WHR-associated gene
Normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: Voretigene neparvovec (DB13932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHR-associated gene variant LYPLAL1/SLC30A10 rs4846567 G allele
Study: 19495810
Drug: Aqua lymphatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqua lymphatic therapy (ALT) for 3 months in addition to self-management therapy
Study: 19495810
Drug: Aqua lymphatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqua lymphatic therapy (ALT)
Study: 9459339
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg enalaprilat intravenously prior to thrombolysis
Study: 7629560
Drug: Ceftazidime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (1 g, intramuscularly administered)
Study: 2535067
Drug: mesoglycan (72
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesoglycan (72 mg/day orally)
Study: 26755506
Drug: New sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: New sedation policy (sequential administration of melatonin, hydroxyzine, and chloral hydrate)
Study: 26755506
Drug: Old sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Old sedation policy (sole administration of chloral hydrate)
Study: 25913070
Drug: Nimorazole (NIM)
Normalized name: nimorazole
DrugBank: Nimorazole (DB12172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimorazole (NIM) administered at a dose of 1.2g/m2, 90 minutes before the first daily radiotherapy (RT) fraction.
Study: 22004601
Drug: Full drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full drug-eluting stent (DES) coverage (n = 90)
Study: 22004601
Drug: Spot drug-eluting
Normalized name: Cold Spot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spot drug-eluting stent (DES) coverage (n = 89)
Study: 16608954
Drug: docetaxel, 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel, 35 mg/m(2) IV infusion (D(35)) on days 1, 8, and 15 every 4 weeks
Study: 16608954
Drug: docetaxel, 40
Normalized name: Docetaxel, 40 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel, 40 mg/m(2) IV (D(40)) on days 1 and 8 every 3 weeks
Study: 16608954
Drug: docetaxel, 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel, 75 mg/m(2) IV (D(75)) on day 1 every 3 weeks
Study: 14511275
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg dose of eletriptan
Study: 10811333
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum (DSM 9843) in a rose-hip drink (400 ml per day, 5 x 10(7) cfu/ml)
Study: 8644026
Drug: Neoton infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoton infusions (30 g/day for 3 days)
Study: 8644026
Drug: Emoxipin injected
Normalized name: Emoxipin
DrugBank: Emoxypine (DB19172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emoxipin injected intramuscularly (3 mg/kg for 20 days)
Study: 8644026
Drug: Emoxipin injected
Normalized name: Emoxipin
DrugBank: Emoxypine (DB19172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emoxipin injected intravenously (10 mg/kg)
Study: 1352245
Drug: xamoterol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: xamoterol (200 mg b.i.d. for 7 days)
Study: 30696041
Drug: MicroLactin® (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MicroLactin® (ML)
Study: 19755572
Drug: Reboxetine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine (4 mg single dose)
Study: 21770829
Drug: Melatonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin treatment (Group A)
Study: 21770829
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no melatonin treatment, Group B)
Study: 21147712
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg iron and 0.4 mg folic acid
Study: 21147712
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg iron, 2.0 mg retinol and 0.4 mg folic acid
Study: 16844502
Drug: Retinyl N‐formyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinyl N‐formyl aspartamate applied twice daily on the left half of the face
Study: 14708457
Drug: Clinidipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinidipine (10 mg)
Study: 12441222
Drug: Quinapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (10 mg)
Study: 11185412
Drug: Gemifloxacin 320
Normalized name: gemifloxacin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 320 mg in fasted state
Study: 11185412
Drug: Gemifloxacin 320
Normalized name: gemifloxacin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 320 mg after a high fat meal
Study: 11185412
Drug: Gemifloxacin 640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 640 mg in fasted state
Study: 11185412
Drug: Gemifloxacin 640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 640 mg after a high fat meal
Study: 1562720
Drug: Consolidation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation therapy (6 days of high-dose cytarabine plus 3 days of amsacrine)
Study: 1562720
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy (2 years of continuous outpatient therapy with cytarabine and 6-thioguanine)
Study: 31601494
Drug: Ketorolac (15-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (15-mg IV every 6 hours)
Study: 31601494
Drug: Acetaminophen (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1-g IV every 6 hours)
Study: 29023185
Drug: Low-Intensity Laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Intensity Laser Therapy (LLLT) - InGaAlP, λ 660 nm, energy density 6 J/cm2, applied daily from the first to the fourth postoperative day.
Study: 26660143
Drug: Secukinumab (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (monthly regimen, baseline, weeks 4, 8)
Study: 16585986
Drug: 0.3% Tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% Tacrolimus gel
Study: 16585986
Drug: 0.5% Tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% Tacrolimus cream
Study: 16585986
Drug: Tacrolimus gel
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus gel and cream
Study: 14644852
Drug: Paracetamol recommended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol recommended
Study: 8834029
Drug: Octreotide (100-micrograms/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100-micrograms/h infusion after a 100-micrograms bolus)
Study: 1410154
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine gum (first dose)
Study: 1410154
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg nicotine gum (second and third doses)
Study: 3907259
Drug: Atropine eye
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine eye drops applied twice a day for 3.5 days
Study: 30219459
Drug: Sunlight exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunlight exposure with vitamin D supplementation (20,000 IU weekly)
Study: 22497677
Drug: bisoprolol 10
Normalized name: bisoprolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bisoprolol 10 mg/day
Study: 18325025
Drug: Citicoline (Cebrolux-Tubilux,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (Cebrolux-Tubilux, Italy, 1600 mg/diem for 60 days)
Study: 16091759
Drug: sequential methotrexate‐fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: sequential methotrexate‐fluorouracil (MF)
Study: 12360462
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (beta-blockers and nitrates)
Study: 8708716
Drug: Low-dose methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methotrexate (40 mg/m2) added to high-dose infusional 5-FU (60 mg/kg over 48 hours) given weekly for 4 weeks and thereafter every 2 and 3 weeks.
Study: 8708716
Drug: High-dose infusional
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose infusional 5-FU without low-dose methotrexate.
Study: 8708716
Drug: High-dose infusional
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose infusional 5-FU with low-dose methotrexate.
Study: 6756933
Drug: muzolimine (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: muzolimine (35 +/- 2 mg/day for six weeks)
Study: 31566689
Drug: Enhanced tablet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced tablet-based book
Study: 31566689
Drug: Basic tablet-based
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic tablet-based book
Study: 17139639
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (UC; exercise therapy and advice)
Study: 12629448
Drug: Functional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional insulin therapy with short-acting insulin analog
Study: 8940672
Drug: Podophyllotoxin cream
Normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Podophyllotoxin cream 0.15%
Study: 8940672
Drug: Podophyllotoxin cream
Normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Podophyllotoxin cream 0.3%
Study: 8940672
Drug: Podophyllotoxin solution
Normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Podophyllotoxin solution 0.5%
Study: 8940672
Drug: Podophyllotoxin cream
Normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Podophyllotoxin cream 0.15% (female)
Study: 8940672
Drug: Podophyllotoxin cream
Normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Podophyllotoxin cream 0.3% (female)
Study: 8940672
Drug: Podophyllotoxin solution
Normalized name: podophyllotoxin
DrugBank: Podofilox (DB01179)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Podophyllotoxin solution 0.5% (female)
Study: 1527313
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray 200 micrograms once a day
Study: 1527313
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aqueous nasal spray 168 micrograms twice a day
Study: 3873880
Drug: Metocurine-pancuronium combination
Normalized name: metocurine
DrugBank: Metocurine (DB01336)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metocurine-pancuronium combination (4:1 ratio by weight) (n = 12)
Study: 27378733
Drug: Home- and
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home- and community-based exercise program (12 weeks, with once-weekly telephone or e-mail support)
Study: 25637265
Drug: Buspirone (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (a partial 5-HT1A receptor agonist)
Study: 21138709
Drug: 0.125 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 g/kg alcohol dose
Study: 9209553
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg alcohol dose
Study: 21138709
Drug: 0.75 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 g/kg alcohol dose
Study: 9209553
Drug: 1.0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g/kg alcohol dose
Study: 14656780
Drug: iv ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iv ondansetron 4 mg
Study: 10195004
Drug: Iodixanol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol (600 mgI kg‐1 bw, 320 mgI ml‐1)
Study: 10195004
Drug: Iopromide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopromide (600 mgI kg‐1 bw, 300 mgI ml‐1)
Study: 7846101
Drug: Dietary gamma-linolenic
Normalized name: gamma-linolenate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary gamma-linolenic acid (GLA) at a dose of 3 g/day for humans and 3 mg/kg/day for rats for 4 months
Study: 7846101
Drug: Dietary gamma-linolenic
Normalized name: gamma-linolenate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary gamma-linolenic acid (GLA) at a dose of 3 mg/kg/day for rats for 4 months
Study: 21600709
Drug: Occupational Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational Therapy Intervention (OTI)
Study: 28258815
Drug: Xylazine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylazine (200 μg kg−1)
Study: 28258815
Drug: Dexmedetomidine (0.875
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.875 μg kg−1)
Study: 25635959
Drug: Occlusal appliance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occlusal appliance therapy (OA)
Study: 19506455
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy with concurrent low-dose daily platinum chemotherapy
Study: 19506455
Drug: Standard fraction
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fraction (conventionally fractionated) radiation therapy
Study: 19506455
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy without concurrent chemotherapy
Study: 19506455
Drug: Treatment (general)
Normalized name: Hongo Killer Treatment
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (general)
Study: 9457819
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy (CHT)
Study: 17075912
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus 10 sessions of twice‐weekly prolonged exposure (PE)
Study: 11709564
Drug: Aminoglutethimide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglutethimide (250 mg daily) for 2 years
Study: 8181847
Drug: Ciprofloxacin, 250
Normalized name: Ciprofloxacin, 250 mg/5 mL oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin, 250 mg twice daily
Study: 8181847
Drug: Ofloxacin, 200
Normalized name: Ofloxacin, 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin, 200 mg twice daily
Study: 31471001
Drug: Website with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Website with vaccine information and interactive social media components
Study: 31471001
Drug: Website with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Website with vaccine information only
Study: 27278272
Drug: Grade 3/4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grade 3/4 Chemotherapy-Induced Neutropenia (CIN)
Study: 27278272
Drug: Grade 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grade 4 Chemotherapy-Induced Neutropenia (CIN)
Study: 18794494
Drug: CTLA4Ig infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CTLA4Ig infusion
Study: 8954018
Drug: NOMA (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOMA (5 mg/day)
Study: 8954018
Drug: NETA (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: NETA (10 mg/day)
Study: 8954018
Drug: NOMA +
Normalized name: Nomacopan
DrugBank: Nomacopan (DB14991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOMA + FLU (250 mg, twice a day)
Study: 8954018
Drug: NETA +
Normalized name: NETARSUDIL
DrugBank: Netarsudil (DB13931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NETA + FLU (250 mg, twice a day)
Study: 1935866
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) plus oral Valium
Study: 31321805
Drug: Consolidative allogeneic
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidative allogeneic hematopoietic stem cell transplantation (allo-HSCT) within three months after CAR-T therapy for MRD-CR patients.
Study: 31321805
Drug: CAR-T therapy
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR-T therapy without subsequent allo-HSCT.
Study: 27883172
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate and a high calorie supplement (2108‐2416 kJ/day)
Study: 27883172
Drug: Placebo testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo testosterone and low calorie supplement (142‐191 kJ/day)
Study: 23017325
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of aspirin (81 mg) and EPA+DHA (3.4 g/d)
Study: 23017325
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg) alone
Study: 23017325
Drug: EPA+DHA (3.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA+DHA (3.4 g/d) alone
Study: 20401350
Drug: GanedenBC(30) -
Normalized name: Ganedenbc 30
DrugBank: Bacillus coagulans (DB19246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GanedenBC(30) - 1 capsule/day for 28 days
Study: 16132930
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate treatment
Study: 12181623
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg per os daily
Study: 12181623
Drug: Clodronate 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 100 mg intramuscularly every 10 days
Study: 30636771
Drug: Formula supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula supplemented with 65 mg/L bOPN (F65)
Study: 30636771
Drug: Formula supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula supplemented with 130 mg/L bOPN (F130)
Study: 26740639
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) - 30 daily sessions of 90 min at 244 kPa
Study: 26740639
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment - 30 daily sessions of 90 min breathing air at 125 kPa
Study: 25108448
Drug: Overall comparison
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall comparison of early vs deferred treatment
Study: 19902033
Drug: N. sativa
Approvals — FDA: no, EMA: no, PMDA: no
Description: N. sativa oil 2.5 ml twice daily, atorvastatin 10 mg once a day, metformin 500 mg twice a day for 6 weeks
Study: 19902033
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg once a day, metformin 500 mg twice a day for 6 weeks
Study: 15830199
Drug: A3 adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A3 adenosine receptor expression in PEX eyes
Study: 1599984
Drug: Amitriptyline combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline combined with a low dose of flupentixol
Study: 3902326
Drug: Iodine concentration
Normalized name: iodine Topical Solution [QuarterMate Concentrate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine concentration higher than 370 mgI/ml
Study: 3902326
Drug: Iodine concentration
Normalized name: iodine Topical Solution [QuarterMate Concentrate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine concentration 370 mgI/ml or lower
Study: 28976895
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg acetylsalicylic acid (ASA) continued
Study: 28976895
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg acetylsalicylic acid (ASA) stopped 72 hours before extraction
Study: 28976895
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg clopidogrel continued
Study: 28976895
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg clopidogrel stopped 72 hours before extraction
Study: 15871196
Drug: 0.375% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375% hyperbaric bupivacaine solutions
Study: 15871196
Drug: 0.375% isobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375% isobaric bupivacaine solutions
Study: 15871196
Drug: 0.375% hypobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.375% hypobaric bupivacaine solutions
Study: 12411141
Drug: Lung protective
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung protective group (n = 34) perfused with hypothermic protective solution to the pulmonary artery
Study: 28336740
Drug: Without intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Without intra-arterial treatment (IAT)
Study: 19453310
Drug: Dopexamine treatment
Normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopexamine treatment
Study: 14699486
Drug: Glucagon (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (bolus of 4.8 microg/kg plus infusion of 9.6 microg x kg(‐1) x h(‐1)) at high intragastric volume (75% of threshold volume for discomfort)
Study: 14699486
Drug: Erythromycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (3 mg/kg) at high intragastric volume
Study: 14699486
Drug: Erythromycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (3 mg/kg) at low intragastric volume (perception threshold)